Thomas Grace, Rahman Ruman
Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham, NG7 2RD, UK.
Curr Oncol Rep. 2025 May;27(5):601-624. doi: 10.1007/s11912-025-01672-4. Epub 2025 Apr 4.
Isocitrate dehydrogenase wild-type glioblastoma is an extremely aggressive and fatal primary brain tumour, characterised by extensive heterogeneity and diffuse infiltration of brain parenchyma. Despite multimodal treatment and diverse research efforts to develop novel therapies, there has been limited success in improving patient outcomes. Constructing physiologically relevant preclinical models is essential to optimising drug screening processes and identifying more effective treatments.
Traditional in-vitro models have provided critical insights into glioblastoma pathophysiology; however, they are limited in their ability to recapitulate the complex tumour microenvironment and its interactions with surrounding cells. In-vivo models offer a more physiologically relevant context, but often do not fully represent human pathology, are expensive, and time-consuming. These limitations have contributed to the low translational success of therapies from trials to clinic. Organoid and glioblastoma-on-a-chip technology represent significant advances in glioblastoma modelling and enable the replication of key features of the human tumour microenvironment, including its structural, mechanical, and biochemical properties. Organoids provide a 3D system that captures cellular heterogeneity and tumour architecture, while microfluidic chips offer dynamic systems capable of mimicking vascularisation and nutrient exchange. Together, these technologies hold tremendous potential for high throughput drug screening and personalised, precision medicine. This review explores the evolution of preclinical models in glioblastoma modelling and drug screening, emphasising the transition from traditional systems to more advanced organoid and microfluidic platforms. Furthermore, it aims to evaluate the advantages and limitations of both traditional and next-generation models, investigating their combined potential to address current challenges by integrating complementary aspects of specific models and techniques.
异柠檬酸脱氢酶野生型胶质母细胞瘤是一种极具侵袭性和致命性的原发性脑肿瘤,其特点是具有广泛的异质性以及脑实质的弥漫性浸润。尽管采取了多模式治疗并为开发新疗法进行了各种研究努力,但在改善患者预后方面取得的成功有限。构建生理相关的临床前模型对于优化药物筛选过程和确定更有效的治疗方法至关重要。
传统的体外模型为胶质母细胞瘤的病理生理学提供了关键见解;然而,它们在重现复杂的肿瘤微环境及其与周围细胞相互作用的能力方面存在局限性。体内模型提供了更具生理相关性的背景,但往往不能完全代表人类病理学情况,且成本高昂、耗时。这些局限性导致了从试验到临床的治疗方法转化成功率较低。类器官和芯片上胶质母细胞瘤技术代表了胶质母细胞瘤建模的重大进展,并能够复制人类肿瘤微环境的关键特征,包括其结构、力学和生化特性。类器官提供了一个能够捕捉细胞异质性和肿瘤结构的三维系统,而微流控芯片则提供了能够模拟血管生成和营养交换的动态系统。总之,这些技术在高通量药物筛选和个性化精准医学方面具有巨大潜力。本综述探讨了胶质母细胞瘤建模和药物筛选中临床前模型的演变,强调了从传统系统向更先进的类器官和微流控平台的转变。此外,它旨在评估传统模型和下一代模型的优缺点,研究它们通过整合特定模型和技术的互补方面来应对当前挑战的综合潜力。